Advertisement

Wiener klinische Wochenschrift

, Volume 124, Issue 3–4, pp 85–99 | Cite as

Konsensus Diagnose und Therapie von Weichteilsarkomen

  • Thomas BrodowiczEmail author
  • Gabriele Amann
  • Andreas Leithner
  • Arpad Sztankay
  • Franz Kainberger
  • Wolfgang Eisterer
  • Bernadette Liegl-Atzwanger
  • Franz Rachbauer
  • Thomas Rath
  • Michael Bergmann
  • Philipp T. Funovics
  • Ferdinand Ploner
  • Reinhard Windhager
Originalarbeit

Zusammenfassung

Die Behandlung von Weichteilsarkomen stellt eine interdisziplinäre Herausforderung dar, die eines spezialisierten Zentrums bedarf. Nur bei entsprechender Kooperation von Chirurgen, Strahlentherapeuten und Onkologen mit den diagnostischen Disziplinen Pathologie und Radiologie, ist die Chance auf das beste erreichbare Behandlungsergebnis für einen individuellen Patienten gewährleistet. Voraussetzung einer effizienten Kommunikation ist die Grundkenntnis der Besonderheiten und Klassifikation von Weichteiltumoren, deren Basis eine Unterteilung in drei Dignitätsgruppen (benigne – intermediär – maligne) darstellt. Der Therapieansatz ist in der Regel multimodal und erfordert entsprechende Infrastrukturen und Erfahrung in der Durchführung von komplexen Therapien.

Schlüsselwörter

Weichteil-sarkom Sarkom Konsensus Österreich Behandlungs-ptad 

Consensus diagnosis and therapy of soft tissue sarcoma

Summary

Soft tissue sarcomas are heterogeneous tumours and relatively uncommon. There have been advances over the past years concerning pathology, clinical behaviour, diagnosis strategies and the treatment. To summarize these advances as well as making it public is one of the goals of the following consensus guidelines. But why do we need special guidelines for Austria? There are international guidelines published by the European Society of Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN). The cause is that we need an explanation of the matrix the ESMO and the NCCN gave according to our clinical practice, the local requirements and facilities in Austria. The following recommendations were drawn up following a consensus meeting of sarcoma specialists from the three high volume centres located at the medical universities in Austria. All fields of involved physicians from diagnosis to therapy worked together to know that soft tissue sarcomas are an interdisciplinary challenge and multimodal treatment is essential. For this reason, these guidelines not only explain but also give the state of the art and clear recommendations. One of the most important guidelines is that any patient with a suspected soft tissue sarcoma should be referred to one of the three university centres and managed by a specialist sarcoma multidisciplinary team. We hope that the consensus is helpful for the clinical practice and improves the quality of care for patients with soft tissue sarcomas in Austria.

Keywords

Soft tissue sarcoma Consensus Austria Multimodality treatment Guidelines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. ESMO Guidelines Working Group, Leyvraz S. Soft tissue sarcomas: ESMO clinical recommandations for diagnosis, treatment and follow-up; Ann Oncol 2007;18(Suppl. 2): ii74–6Google Scholar
  2. Casali PG, Blay JY. On behalf of the ESMO/CONTICANET/EUROBONET Consensus Panel of experts: Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up; Ann Oncol 2010;21(Suppl. 5): v189–v203Google Scholar
  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009; CA Cancer J Clin 2009; 59(4):225–49PubMedCrossRefGoogle Scholar
  4. Wibmer C, Leithner A, Zielonke N, Sperl M, Windhager R. Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol 2010;21(5):1106–11PubMedCrossRefGoogle Scholar
  5. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005;353(7):701–11PubMedCrossRefGoogle Scholar
  6. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91(10):1914–26PubMedCrossRefGoogle Scholar
  7. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification; Histopathology 2006;48(1):3–12PubMedCrossRefGoogle Scholar
  8. Ploner F, Zacherl J, Wrba F, Längle F, Bareck E, Eisterer W, et al. Gastrointestinal stromal tumors: Recommandations on diagnosis, therapy and follow-up care in Austria. Wien Klin Wochenschr 2009;121(23–24):780–90PubMedCrossRefGoogle Scholar
  9. Froehner M, Wirth P. Etiologic factors in soft tissue sarcomas. Onkologie 2001;24(2):139–42PubMedCrossRefGoogle Scholar
  10. Van Dyck P, Gielen J, Vanhoenacker F, De Schepper A. General Imaging Strategy of Soft Tissue Tumors. In: De Schepper AM (Ed.): Imaging of Soft Tissue Tumors; Springer-Verlag Berlin Heidelberg 2006; 3rd Edition; page 163–166CrossRefGoogle Scholar
  11. Gielen J, Ceulemans R. Ultrasound of Soft Tissue Tumors. In: De Schepper AM (Ed.): Imaging of Soft Tissue Tumors. Springer-Verlag Berlin Heidelberg 2006; 3rd Edition; page 3–18CrossRefGoogle Scholar
  12. Brisse H, Orbach D, Klijanienko J, Fréneaux P, Neuenschwander S. Imaging and diagnostic strategy of soft tissue tumors in children. Eur Radiol 2006;16(5):1147–64PubMedCrossRefGoogle Scholar
  13. Griffith JF, Chan DP, Kumta SM, Chow LT, Ahuja AT. Does Doppler analysis of musculoskeletal soft-tissue tumours help predict tumour malignancy? Clin Radiol 2004;59(4):369–75PubMedCrossRefGoogle Scholar
  14. Lakkaraju A, Sinha R, Garikipati R, Edward S, Robinson P. Ultrasound for initial evaluation and triage of clinically suspicious soft-tissue masses. Clin Radiol 2009;64(6):615–21PubMedCrossRefGoogle Scholar
  15. De Schepper AM, De Beuckeleer L, Vandevenne J, Somville J. Magnetic resonance imaging of soft tissue tumors. Eur Radiol 2000;10(2):213–23PubMedCrossRefGoogle Scholar
  16. Morrison WB, Dalinka MK, Daffner RH, DeSmet AA, El-Khoury GY, Kneeland JB, et al. Expert Panel on Musculosketal Imaging. Soft tissue Masses. Date of origin: 1995 Last review date: 2009; online publication; http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/ExpertPanelonMusculoskeletalImaging/SoftTissueMassesDoc19.aspx
  17. Wu JS, Hochman MG. Soft-tissue tumors and tumorlike lesions: a systematic imaging approach. Radiology 2009;253:297–316PubMedCrossRefGoogle Scholar
  18. Ward WG Sr, Rougraff B, Quinn R, Damron T, O'Connor MI, Turcotte RE, et al. Tumors masquerading as hematomas. Clin Orthop Res 2007;465:232–40Google Scholar
  19. Jelinek J, Malawer M, Sternheim A, Ferraro R, Beaman F, Henshaw R, et al. Clinical presentation, outcome and MR findings of soft tissue tumors presenting as hematomas. Skeletal Radiol 2009;38:399–400CrossRefGoogle Scholar
  20. Christie-Large M, James SL, Tiessen L, Davies AM, Grimer RJ. Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer 2008;44(13):1841–5PubMedCrossRefGoogle Scholar
  21. Reske SN, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 2001;28(11):1707–23PubMedCrossRefGoogle Scholar
  22. Landa J, Schwartz LH. Contemporary Imaging in Sarcoma. The Oncologist 2009;14(10):1021–38PubMedCrossRefGoogle Scholar
  23. Windhager R, Hovy L, Prietzel T, von Salis-Soglio G: AWMF Leitlinie Weichteilsarkome der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC) und des Berufsverbandes der Ärzte für Orthopädie, 2002Google Scholar
  24. Leithner A, Windhager R. Leitlinien der Biopsie von Knochen- und Weichteiltumoren. Orthopäde 2007;36(2):167–74PubMedCrossRefGoogle Scholar
  25. Leithner A, Maurer-Ertl W, Windhager R. Biopsy of bone and soft tissue tumours: hints and hazards. Recent Results Cancer Res 2009;179:3–10PubMedCrossRefGoogle Scholar
  26. Fletcher CDM, Unni KK, Mertens F (Hg). WHO Classification of Tumours, Volume 5, Lyons 2002; nachzulesen auch auf der Webseite der IARC unter www.iarc.fr/en/publications/pdfs-online/pat-gen/bb5/BB5.pdf
  27. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359(9314):1301–7PubMedCrossRefGoogle Scholar
  28. Coindre JM, Terrier P, Bui NB, Bonichon F, Collin F, Le Doussal V, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996;14(3):869–77PubMedGoogle Scholar
  29. Costa J. The grading and staging of soft tissue sarcomas. In Fletcher CD, McKee PH (Hg.): Pathobiology of soft tissue tumors. Churchill Livingstone. Edinburgh 1990;pp. 221Google Scholar
  30. Coindre JM, Trojani M, Contesso G, David M, Rouesse J, Bui NB, et al. Reproucibility of a histopathologic grading system for adult soft tissue sarcoma; Cancer 1986;58(2):306–9PubMedCrossRefGoogle Scholar
  31. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sacomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91(10):1914–26PubMedCrossRefGoogle Scholar
  32. Gustafson P, Dreinhofer KE, Rydholm A. Soft tissue sarcoma should be treated at a tumor center. A comparison of quality of surgery in 375 patients. Acta Orthop Scand 1994;65(1):47–50PubMedCrossRefGoogle Scholar
  33. LeVay J, O'Sullivan B, Catton C, Bell R, Fornasier V, Cummings B, et al. Outcome and prognostic factors in soft tissue sarcoma in the adult. Int J Radiat Oncol Biol Phys 1993;27(5):1091–9PubMedCrossRefGoogle Scholar
  34. Dinges S, Budach V, Budach W, Feldmann HJ, Stuschke M, Sack H. Local recurrence of soft sarcomas in adults: a retrospective analysis of prognostic factors in 102 cases after surgery and radiation therapy. Eur J Cancer 1994;30A(11):1636–42PubMedCrossRefGoogle Scholar
  35. Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14(5):1679–89PubMedGoogle Scholar
  36. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculosceletal sarcoma. Clin Orthop Relat Res 1980;153:106–20PubMedGoogle Scholar
  37. Malawer MM, Sugarbaker PH. Musculosceletal Cancer Surgery. Treatment of Sarcomas and Allied Diseases. Kluwer Academic Publishers 2001Google Scholar
  38. Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities. prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196(3):305–15PubMedCrossRefGoogle Scholar
  39. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14(3):859–68PubMedGoogle Scholar
  40. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16(1):197–203PubMedGoogle Scholar
  41. Choong PF, Petersen IA, Nascimento AG, Sim FH. Is radiotherapy important for low-grade soft tissue sarcoma of the extremity? Clin Orthop Relat Res 2001;387:191–9PubMedCrossRefGoogle Scholar
  42. Jebsen N, Trovik CS, Bauer HC, Rydholm A, Monge OR, Hall KS, et al. Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study. Int J Radiat Oncol Biol Phys 2008;71(4):1196–203PubMedCrossRefGoogle Scholar
  43. Barkley HT Jr, Martin RG, Romsdahl MM, Lindberg R, Zagars GK. Treatment of soft tissue sarcomas by preoperative irradiation and conservative surgical resection. Int J Radiat Oncol Biol Phys 1988;14(4):693–9PubMedCrossRefGoogle Scholar
  44. Suit HD, Spiro I. Role of radiation in the management of adult patients with sarcoma of soft tissue. Semin Surg Oncol 1994;10(5):347–56PubMedCrossRefGoogle Scholar
  45. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 2002;359(9325):2235–41PubMedCrossRefGoogle Scholar
  46. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Preoperative vs. postoperative radiation therapy for soft tissue sarcoma: a retrospective comparative evaluation of disease outcome. Int J Radiat Oncol Biol Phys 2003;56(2):482–8PubMedCrossRefGoogle Scholar
  47. Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol 1996;61(2):90–9PubMedCrossRefGoogle Scholar
  48. Davis AM, O'Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol 2005;75(1):48–53PubMedCrossRefGoogle Scholar
  49. Sindelar WF, Kinsella TJ, Chen PW, DeLaney TF, Tepper JE, Rosenberg SA, et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg 1993;128(4):402–10PubMedCrossRefGoogle Scholar
  50. Alektiar KM, Hu K, Anderson L, Brennan MF, Harrison LB. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 2000;47(1):157–63PubMedCrossRefGoogle Scholar
  51. Rachbauer F, Sztankay A, Kreczy A, Sununu T, Bach C, Nogler M, et al. High-dose-rate intraoperative brachytherapy (IOHDR) using flab technique in the treatment of soft tissue sarcomas. Strahlenther Onkol 2003;179(7):480–5PubMedGoogle Scholar
  52. Niewald M, Fleckenstein J, Licht N, Bleuzen C, Ruebe C. Intraoperative radiotherapy (IORT) combined with external beam radiotherapy (EBRT) for soft-tissue sarcomas – a retrospective evaluation of the Homburg experience in the years 1995–2007; Radiat Oncol 2009;4:32PubMedCrossRefGoogle Scholar
  53. Wanebo HJ, Temple WJ, Popp MB, Constable W, Aron B, Cunningham SL. Preoperative regional therapy for extremity sarcoma. A tricenter update Cancer 1995;75(9):2299–306Google Scholar
  54. Sauer R, Schuchardt U, Hohenberger W, Wittekind C, Papadopoulos T, Grabenbauer GG, et al. Neoadjuvant rediochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control. Strahlenther Onkol 1999;175(6):259–66PubMedCrossRefGoogle Scholar
  55. DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56(4):1117–27PubMedCrossRefGoogle Scholar
  56. Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremeties and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006;24(4):619–25PubMedCrossRefGoogle Scholar
  57. Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005;63(3):852–9PubMedCrossRefGoogle Scholar
  58. Schwarz R, Krüll A, Engenhart-Cabillic R, Favre A, Prott FJ, Auberger T, et al. European results of neutron therapy in soft tissue sarcomas, Recent Results Cancer Res 1998;150:100–12PubMedCrossRefGoogle Scholar
  59. Greiner R, Munkel G, Kann R, Blattmann H, Coray A, Thum P, et al. Pion irradiation at Paul Scherrer Institute. Results of dynamic treatment of unresectable soft tissue sarcoma. Strahlenther Onkol 1990;166(1):30–3PubMedGoogle Scholar
  60. Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999;91(3):432–9PubMedCrossRefGoogle Scholar
  61. Debus J, Schulz-Ertner D, Schad L, Essig M, Rhein B, Thillmann CO, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. Int J Radiat Oncol Biol Phys 2000;47(3):591–6PubMedCrossRefGoogle Scholar
  62. Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jäkel O, et al. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007;68(2):449–57PubMedCrossRefGoogle Scholar
  63. Schuetze SM, Patel S. Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? Oncologist 14(10):1003–12Google Scholar
  64. Blay JY, Le Cesne A. Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. Oncologist 2009;14(10):1013–20PubMedCrossRefGoogle Scholar
  65. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults. meta-analysis of individual data. Lancet 1997;350(9092):1647–54CrossRefGoogle Scholar
  66. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma Cancer 2008;113(3):573–81PubMedCrossRefGoogle Scholar
  67. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19(5):1238–47PubMedGoogle Scholar
  68. Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma – reduced local recurrence but not improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12(6):1137–49PubMedGoogle Scholar
  69. Woll PJ, van Glabbeke M, Hohenberger P, Le Cesne A, Gronchi A, Hoeksta HJ, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial. J Clin Oncol 2007; 25(18S): Abstract 10008Google Scholar
  70. Kattan MW, Leung DHY, Brennan MF: Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002;20:791–6PubMedCrossRefGoogle Scholar
  71. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, et al. Validation and adaptation of a nomogram for predecting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005;103:402–8PubMedCrossRefGoogle Scholar
  72. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: A european organisation for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol 2007;25:3144–50PubMedCrossRefGoogle Scholar
  73. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the european organisation for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 1995;13:1537–45PubMedGoogle Scholar
  74. Morgan JA, Le Cesne A, Chawla S, von Mehren M, Schuetze S, Casali PG, et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide (I). J Clin Oncol 2007. ASCO Annual Proceedings Part I, 25(18S): Abstract 10060Google Scholar
  75. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22(8):1480–90PubMedCrossRefGoogle Scholar
  76. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22(5):890–9PubMedCrossRefGoogle Scholar
  77. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23(3):576–84PubMedCrossRefGoogle Scholar
  78. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, et al. Efficacy and Safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: Results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27(25):4188–96PubMedCrossRefGoogle Scholar
  79. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20(12):2824–31PubMedCrossRefGoogle Scholar
  80. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22(9):1706–12PubMedCrossRefGoogle Scholar
  81. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25(19):2755–63PubMedCrossRefGoogle Scholar
  82. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27(19):3133–40PubMedCrossRefGoogle Scholar
  83. Ryan CW, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol 2008;26(Suppl.): Abstract 10532Google Scholar
  84. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27(19):3154–60PubMedCrossRefGoogle Scholar
  85. Agulnik M, Okuno SH, Von Mehren M, Jovanovic B, Brockstein B, Benjamin RS, et al. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol 2009;27(Suppl.): Abstract 10522Google Scholar
  86. Pink D, Rahm J, Schoeler D, Schoenknect TM, Reichardt P. Activity of paclitaxel in radiation induced and other secondary angiosarcomas. J Clin Oncol 2009;27(Suppl.): Abstract 10578Google Scholar
  87. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol 2008;26:5269–74PubMedCrossRefGoogle Scholar
  88. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 1.2011Google Scholar
  89. Blackmon SH, Shah N, Roth JA, Correa AM, Vaporciyan AA, Rice DC, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 2009;88:877–85PubMedCrossRefGoogle Scholar
  90. Issels RD. High-risk soft tissue sarcoma. clinical trial and hyperthermia combined chemotherapy. Int J Hyperthermia 2006;22(3):235–9PubMedCrossRefGoogle Scholar
  91. Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BD, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. The Lancet Oncology 2010;11(6):561–70PubMedCrossRefGoogle Scholar
  92. Lahat G, Anaya DA, Wang X, Tuvin D, Lev D, Pollock RE. Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Onocl 2008;15(6):1585–93CrossRefGoogle Scholar
  93. Engström K, Bergh P, Gustafson P, Hultborn R, Johansson H, Löfvenberg R, et al. Liposarcoma. outcome based on the Scandinavian Sarcoma Group register. Cancer 2008;113(7):1649–56PubMedCrossRefGoogle Scholar
  94. Lehnert T, Cardona S, Hinz U, Willeke F, Mechtersheimer G, Treiber M, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol 2009;35(9):986–93PubMedCrossRefGoogle Scholar
  95. Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2.084 localized primary adult soft tissue sarcomas. Ann Surg 2002;235(3):424–34PubMedCrossRefGoogle Scholar
  96. Anaya DA, Lahat G, Liu J, Xing Y, Cornier JN, Pisters PW, Lev DC, et al. Multifocality in retroperitoneal sarcoma. A prognostic factor critical to surgical decision-making. Ann Surg 2009;249(1):137–42PubMedCrossRefGoogle Scholar
  97. Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay JY, et al. Primary retroperitoneal sarcomas. A multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009;27(1):31–37PubMedCrossRefGoogle Scholar
  98. Sampath S, Hitchcock YJ, Shrieve DC, Randall RL, Schultheiss TE, Wong JY. Radiotherapy and extent of surgical resection in retroperitoneal soft-tissue sarcoma: Multi-institutional analysis of 261 patients. J Surg Oncol 2010; Jan 29 (Epub ahaed of print)Google Scholar
  99. Petersen IA, Haddock MG, Donohue JH, Nagorney DM, Grill JP, Sargent DJ, et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys 2002;52(2):469–75PubMedCrossRefGoogle Scholar
  100. Dziewirski W, Rutkowski P, Nowecki Zl, Salamacha M, Morysinski T, Kulik A, et al. Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas. Ann Surg Oncol 2006;13(2):245–52PubMedCrossRefGoogle Scholar
  101. Zacherl M, Leithner A, Koch H, Windhager R. Weichteilsarkome – jeder zweite Patient inadäquat therapiert. Wiener Klin Magazin 2006;1:22–8Google Scholar
  102. Zacherl M, Giessauf C, Glehr M, Gruber G, Maurer-Ertl W, Schwantzer G, et al. Revision of inadequately treated soft-tissue sarcoma is associated with increased need for plastic or reconstructive surgery. Eur Surg 2009;41(4):155–62CrossRefGoogle Scholar
  103. Candrasekar CR, Wafa H, Grimer RJ, Carter SR, Tillman RM, Abudu A. The effect of an unplanned excision of a soft-tissue sarcoma on prognosis. J Bone Joint Surg Br 2008;90(2):203–8CrossRefGoogle Scholar
  104. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy Cancer 2003;97(10);2544–53PubMedCrossRefGoogle Scholar
  105. Zagars GK, Ballo MT. Sequencing radiotherapy for soft tissue sarcoma when re-resection is planned. Int J Radiat Oncol Biol Phys 2003;56(1):21–7PubMedCrossRefGoogle Scholar
  106. Kepka L, Suit HD, Goldberg SI, Rosenberg AE, Gebhardt MC, Hornicek FJ, et al. Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol 2005;92(1):39–45PubMedCrossRefGoogle Scholar
  107. Funovics PT, Vaselic S, Panotopoulos J, Kotz RI, Dominkus M. The impact of re-excision of inadequately resected soft tissue sarcomas on surgical therapy, results and prognosis: a single institution experience with 682 patients. J Surg Oncol 2010;102(6):626–33PubMedCrossRefGoogle Scholar
  108. Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Semin Oncol 2003;30(3):413–6PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Thomas Brodowicz
    • 1
    Email author
  • Gabriele Amann
    • 2
  • Andreas Leithner
    • 3
  • Arpad Sztankay
    • 4
  • Franz Kainberger
    • 5
  • Wolfgang Eisterer
    • 6
  • Bernadette Liegl-Atzwanger
    • 7
  • Franz Rachbauer
    • 8
  • Thomas Rath
    • 9
  • Michael Bergmann
    • 10
  • Philipp T. Funovics
    • 12
  • Ferdinand Ploner
    • 11
  • Reinhard Windhager
    • 12
  1. 1.Klinische Abteilung für OnkologieUniversitätsklinik für Innere MedizinWienAustria
  2. 2.Klinisches Institut für PathologieMedizinische Universität WienAustria
  3. 3.Universitätsklinik für Orthopädie und orthopädische ChirurgieGrazAustria
  4. 4.Universitätsklinik für Strahlentherapie-RadioonkologieMedizinische Universität InnsbruckAustria
  5. 5.Abteilung für Neuro- und muskuloskeletale RadiologieUniversitätsklinik für RadiodiagnostikWienAustria
  6. 6.Universitätsklinik für Innere Medizin IInnsbruckAustria
  7. 7.Institut für PathologieMedizinische Universität GrazAustria
  8. 8.Universitätsklinik für OrthopädieInnsbruckAustria
  9. 9.Klinische Abteilung für Wiederherstellungs- und Plastische ChirurgieUniversitätsklinik für ChirurgieWienAustria
  10. 10.Abteilung für AllgemeinchirurgieMedizinische Universität WienWienAustria
  11. 11.Klinische Abteilung für OnkologieUniversitätsklinik für Innere MedizinGrazAustria
  12. 12.Universitätsklinik für OrthopädieWienAustria

Personalised recommendations